What Is FTPP Adipotide?
FTPP Adipotide, also known as Adipotide or Prohibitin-Targeting Peptide 1, is a synthetic chimeric peptidomimetic composed of two peptide components joined by a glycine linker. The first component is the CKGGRAKDC targeting sequence, while the second is the D-amino-acid peptide D(KLAKLAK)₂. This design gives FTPP Adipotide a defined molecular architecture consisting of a targeting domain and a proapoptotic peptide domain.
The compound is therefore classified as a peptide-based molecular targeting construct, rather than a conventional small-molecule compound. Its primary molecular target reported in the original research is prohibitin (PHB), a protein associated with the vascular endothelium of white adipose tissue.
Research Overview Table
Chemical and Molecular Characteristics
FTPP Adipotide is a synthetic chimeric peptidomimetic composed of the CKGGRAKDC targeting motif linked through a glycine-glycine spacer to the D-amino-acid sequence D(KLAKLAK)₂. The CKGGRAKDC motif contains two cysteine residues that form a cyclic structure, while the C-terminal domain is composed of D-amino acids. This two-part architecture is a defining structural feature of the compound.
The molecular formula recorded for Adipotide is C111H206N36O28S2, with a molecular weight of 2555.2 g/mol.
Certificates:
Mechanism of Action Under Investigation
FTPP Adipotide targets prohibitin (PHB) through the CKGGRAKDC motif. The motif binds PHB on the surface of vascular endothelial cells in white adipose tissue, and the PHB-associated targeting system supports peptide internalization. PHB also interacts with annexin A2 (ANXA2) within membrane lipid rafts.
After internalization, the D(KLAKLAK)₂ domain disrupts mitochondrial membranes. Experimental studies associate this activity with mitochondrial damage and activation of apoptotic cell-death processes.
Researchers have examined the PHB-targeting interaction using phage-display screening, peptide-binding studies, and protein-interaction experiments. Cellular and biochemical studies have examined peptide internalization and mitochondrial effects.
The precise role of the PHB/ANXA2 complex in FTPP Adipotide internalization remains uncertain. The studies establish the PHB–ANXA2 interaction and PHB's role in targeting, but they do not fully define how this membrane complex contributes to Adipotide uptake or how each component contributes to the downstream mitochondrial response.
Scientific Research Context
FTPP Adipotide has been studied in experimental research involving adipose tissue vascular biology and peptide targeting. The literature includes in vitro studies as well as animal research in rodents and nonhuman primates. Most of the available evidence comes from these preclinical systems, so the current research base remains predominantly preclinical.
FTPP Adipotide Biology and Biological Pathways
Primary Biological Function
Prohibitin 1 (PHB1) functions in several cellular compartments and has well-established roles in mitochondrial structure and function. Within the mitochondrial inner membrane, PHB1 forms complexes with PHB2 and helps maintain mitochondrial organization. Studies also show that PHB1 occurs at the cell surface of adipocytes and adipose endothelial cells, where it participates in cellular functions distinct from its mitochondrial role.
Relevant Metabolic or Signaling Pathways
PHB1 has been studied in fatty-acid transport and mitochondrial fuel metabolism. In adipose tissue, PHB1 forms a complex with annexin A2 and CD36 that participates in long-chain fatty-acid transport. Other studies have linked PHB1 to pyruvate carboxylase activity and fatty-acid oxidation in adipocytes. These pathways are investigated to define how PHB1 regulates lipid and energy metabolism at the cellular level.
Tissue-Specific Biology
PHB1 occurs on the cell surface of adipose endothelial cells and adipocytes in white and brown adipose tissue. In white adipose tissue, PHB1 interacts with annexin A2 and CD36 at the cell surface. Endothelial PHB1 also participates in long-chain fatty-acid transport in both white and brown adipose tissue.
Experimental Biomarkers
PHB1, ANXA2, and CD36 provide molecular markers for examining the PHB-associated fatty-acid transport system in adipose tissue. Experimental studies have also measured long-chain fatty-acid transport, triglyceride clearance, free fatty acids, glucose clearance, mitochondrial respiration, and UCP1 expression in models of PHB function.
Laboratory Investigation Methods
Researchers have examined PHB biology using cell culture, PHB knockout models, immunofluorescence, protein-interaction assays, and fatty-acid transport assays. Studies have also used transwell systems, radiolabeled fatty acids, BODIPY-labeled fatty acids, Western blotting, and mitochondrial respiration measurements to examine PHB related cellular processes.
Experimental Models Used in Published Research
Published FTPP Adipotide research includes cell-based systems, rodent models, and nonhuman primates. These models have been used to examine the compound at the cellular, tissue, and organismal levels.
Cell-Based Models
Endothelial cell cultures and adipose-derived cell models have been used in FTPP Adipotide research. Their main limitation is that isolated cells do not reproduce the tissue architecture, vascular structure, or multicellular environment of intact adipose tissue.
Mouse Models
Genetically obese and diet-induced obese mice have been used as the main rodent models for FTPP Adipotide research. Their limitation is the species difference between mouse and human adipose biology, which restricts direct translation of findings to humans.
Rat Models
Obese rat models are represented in the preclinical literature on FTPP Adipotide. Their main limitation is the biological difference between rat and human adipose tissue, which limits direct translation of findings to humans.
Nonhuman Primate Models
Rhesus macaques, baboons, and cynomolgus macaques are the nonhuman primate models reported for FTPP Adipotide. Their main limitation is that they remain animal models, so findings from these species cannot establish responses in humans.
FTPP Adipotide Published Research
Prohibitin-Targeting Peptide Development
Researchers investigated peptide sequences that home to white adipose tissue vasculature and identified CKGGRAKDC as a vascular-targeting motif. They then examined its association with prohibitin on adipose vascular endothelium and used the targeting sequence in the development of Adipotide.
Adipose Vascular Biology
Subsequent research investigated FTPP Adipotide as a vascular-targeting peptide construct in the context of white adipose tissue. The studies examined its association with adipose vascular tissue and the resulting cellular and tissue changes. The evidence remains preclinical, and the published work does not establish whether these findings translate to humans.
Obesity-Related Metabolic Research
Researchers also investigated FTPP Adipotide in relation to adipose tissue mass, glucose regulation, insulin sensitivity, and metabolic changes in experimental obesity. These studies reported changes in several metabolic measures alongside alterations in adipose tissue. The observations come from preclinical research and therefore do not establish clinical efficacy.
Renal Effects
The primate study investigated renal function and kidney tissue changes following FTPP Adipotide exposure. The researchers examined serum creatinine, blood urea nitrogen, urinary parameters and renal histology, with particular attention to the proximal tubules. The study also investigated whether the renal changes reversed after treatment ended.
Limitations of Current Research
Evidence Is Predominantly Preclinical
Research on FTPP Adipotide has remained largely preclinical, with most published evidence coming from laboratory and animal studies. Human research is much more limited.
Human Clinical Evidence
A first-in-human Phase I study of Prohibitin-TP01 enrolled four participants before the study was terminated. The study record contains no posted clinical results, so the human evidence remains very limited.
Species Differences
Differences in adipose and metabolic biology between rodents and primates limit direct comparison of preclinical findings across species. The Adipotide literature specifically notes differences in adipokines, peptide hormones, neurotransmitter responses, and feeding patterns between these species.
Study Design Limitations
The available FTPP Adipotide studies use different experimental designs and study conditions, which limits direct comparison across the evidence base. The first-in-human study used a single-group, open-label Phase I design, and enrolled four participants before termination. No study results were posted, further limiting interpretation of the clinical evidence.
Independent Replication
The FTPP Adipotide literature contains a relatively small number of primary research programs. Several important observations come from closely related experimental studies rather than a large body of independent replication. The limited size of the literature makes it difficult to assess how consistently all reported findings reproduce across independent research groups.
Long-Term Evidence
Long-term human evidence for FTPP Adipotide is not available. The registered Phase I study planned a one-year follow-up, including monitoring of kidney function and other clinical measures, but the study was terminated and no results were posted.
Analytical Documentation
High-performance liquid chromatography (HPLC) can assess peptide purity by separating the intended compound from related impurities and degradation products. Liquid chromatography–mass spectrometry (LC-MS) can provide molecular-mass information to support compound identity. For a peptide of this structural complexity, LC-MS and HPLC provide complementary information rather than interchangeable measurements.
Nuclear magnetic resonance (NMR) may provide additional structural information when a suitable sample and validated method are available, although it is not routinely required for every peptide batch. A Certificate of Analysis (COA) records batch-specific analytical results and links them to the corresponding material. Analytical documentation is important because it allows laboratory researchers to verify the identity and quality of the material being studied. Analytical documentation verifies product identity and quality, not biological performance.
Storage and Laboratory Handling
Store FTPP Adipotide at 2–8°C, as specified on the supplied Certificate of Analysis. Keep the lyophilized material in a sealed container and protect it from moisture, light and unnecessary temperature changes. Follow the storage conditions provided with the specific batch documentation.
Handle the material in a clean laboratory environment using appropriate contamination control practices. Qualified laboratory personnel should manage the material and maintain accurate batch and storage records. Keep the container properly sealed when not in use and follow applicable laboratory procedures. FTPP Adipotide is supplied for laboratory research use only.
Frequently asked questions
Why choose us?
Direct SARMs is an established supplier of research peptides. We are committed to product quality, reliable service, and helpful customer support.
Our European-made products undergo rigorous purity testing, with clear product information provided for each research material. We also aim to provide dependable shipping and a smooth ordering experience.
Our support team is available to assist with orders, shipping, payments, and general questions. At Direct SARMs, we aim to make the research supply process simple, clear, and reliable.